The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer

Joseph M. Herman, Amol Narang, Kent A. Griffith, Mark M. Zalupski, Jennifer Barsky Reese, Susan L Gearhart, Nilofer Azad, June Chan, Leah Olsen, Jonathan Efron, Theodore S. Lawrence, Edgar Ben-Josef

Research output: Contribution to journalArticle

Abstract

Purpose: Existing studies that examine the effect of neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer on patient quality of life (QOL) are limited. Our goals were to prospectively explore acute changes in patient-reported QOL endpoints during and after treatment and to establish a distribution of scores that could be used for comparison as new treatment modalities emerge. Methods and Materials: Fifty patients with locally advanced rectal cancer were prospectively enrolled at 2 institutions. Validated cancer-specific European Organization for Research and Treatment of Cancer (EORTC QLQ-CR30) and colorectal cancer-specific (EORTC QLQ-CR38 and EORTC QLQ-CR 29) QOL questionnaires were administered to patients 1 month before they began CRT, at week 4 of CRT, and 1 month after they had finished CRT. The questionnaires included multiple symptom scales, functional domains, and a composite global QOL score. Additionally, a toxicity scale was completed by providers 1 month before the beginning of CRT, weekly during treatment, and 1 month after the end of CRT. Results: Global QOL showed a statistically significant and borderline clinically significant decrease during CRT (-9.50, P=.0024) but returned to baseline 1 month after the end of treatment (-0.33, P=.9205). Symptoms during treatment were mostly gastrointestinal (nausea/vomiting +9.94, P

Original languageEnglish (US)
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume85
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Rectal Neoplasms
cancer
Quality of Life
Therapeutics
vomiting
nausea
toxicity
Nausea
Vomiting
Colorectal Neoplasms
Neoplasms
Organizations
composite materials
Research

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer. / Herman, Joseph M.; Narang, Amol; Griffith, Kent A.; Zalupski, Mark M.; Reese, Jennifer Barsky; Gearhart, Susan L; Azad, Nilofer; Chan, June; Olsen, Leah; Efron, Jonathan; Lawrence, Theodore S.; Ben-Josef, Edgar.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 85, No. 1, 01.01.2013.

Research output: Contribution to journalArticle

Herman, Joseph M. ; Narang, Amol ; Griffith, Kent A. ; Zalupski, Mark M. ; Reese, Jennifer Barsky ; Gearhart, Susan L ; Azad, Nilofer ; Chan, June ; Olsen, Leah ; Efron, Jonathan ; Lawrence, Theodore S. ; Ben-Josef, Edgar. / The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer. In: International Journal of Radiation Oncology, Biology, Physics. 2013 ; Vol. 85, No. 1.
@article{5a298a2e9b7644ec86e5988b68a86967,
title = "The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer",
abstract = "Purpose: Existing studies that examine the effect of neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer on patient quality of life (QOL) are limited. Our goals were to prospectively explore acute changes in patient-reported QOL endpoints during and after treatment and to establish a distribution of scores that could be used for comparison as new treatment modalities emerge. Methods and Materials: Fifty patients with locally advanced rectal cancer were prospectively enrolled at 2 institutions. Validated cancer-specific European Organization for Research and Treatment of Cancer (EORTC QLQ-CR30) and colorectal cancer-specific (EORTC QLQ-CR38 and EORTC QLQ-CR 29) QOL questionnaires were administered to patients 1 month before they began CRT, at week 4 of CRT, and 1 month after they had finished CRT. The questionnaires included multiple symptom scales, functional domains, and a composite global QOL score. Additionally, a toxicity scale was completed by providers 1 month before the beginning of CRT, weekly during treatment, and 1 month after the end of CRT. Results: Global QOL showed a statistically significant and borderline clinically significant decrease during CRT (-9.50, P=.0024) but returned to baseline 1 month after the end of treatment (-0.33, P=.9205). Symptoms during treatment were mostly gastrointestinal (nausea/vomiting +9.94, P",
author = "Herman, {Joseph M.} and Amol Narang and Griffith, {Kent A.} and Zalupski, {Mark M.} and Reese, {Jennifer Barsky} and Gearhart, {Susan L} and Nilofer Azad and June Chan and Leah Olsen and Jonathan Efron and Lawrence, {Theodore S.} and Edgar Ben-Josef",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.ijrobp.2012.09.006",
language = "English (US)",
volume = "85",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer

AU - Herman, Joseph M.

AU - Narang, Amol

AU - Griffith, Kent A.

AU - Zalupski, Mark M.

AU - Reese, Jennifer Barsky

AU - Gearhart, Susan L

AU - Azad, Nilofer

AU - Chan, June

AU - Olsen, Leah

AU - Efron, Jonathan

AU - Lawrence, Theodore S.

AU - Ben-Josef, Edgar

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Purpose: Existing studies that examine the effect of neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer on patient quality of life (QOL) are limited. Our goals were to prospectively explore acute changes in patient-reported QOL endpoints during and after treatment and to establish a distribution of scores that could be used for comparison as new treatment modalities emerge. Methods and Materials: Fifty patients with locally advanced rectal cancer were prospectively enrolled at 2 institutions. Validated cancer-specific European Organization for Research and Treatment of Cancer (EORTC QLQ-CR30) and colorectal cancer-specific (EORTC QLQ-CR38 and EORTC QLQ-CR 29) QOL questionnaires were administered to patients 1 month before they began CRT, at week 4 of CRT, and 1 month after they had finished CRT. The questionnaires included multiple symptom scales, functional domains, and a composite global QOL score. Additionally, a toxicity scale was completed by providers 1 month before the beginning of CRT, weekly during treatment, and 1 month after the end of CRT. Results: Global QOL showed a statistically significant and borderline clinically significant decrease during CRT (-9.50, P=.0024) but returned to baseline 1 month after the end of treatment (-0.33, P=.9205). Symptoms during treatment were mostly gastrointestinal (nausea/vomiting +9.94, P

AB - Purpose: Existing studies that examine the effect of neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer on patient quality of life (QOL) are limited. Our goals were to prospectively explore acute changes in patient-reported QOL endpoints during and after treatment and to establish a distribution of scores that could be used for comparison as new treatment modalities emerge. Methods and Materials: Fifty patients with locally advanced rectal cancer were prospectively enrolled at 2 institutions. Validated cancer-specific European Organization for Research and Treatment of Cancer (EORTC QLQ-CR30) and colorectal cancer-specific (EORTC QLQ-CR38 and EORTC QLQ-CR 29) QOL questionnaires were administered to patients 1 month before they began CRT, at week 4 of CRT, and 1 month after they had finished CRT. The questionnaires included multiple symptom scales, functional domains, and a composite global QOL score. Additionally, a toxicity scale was completed by providers 1 month before the beginning of CRT, weekly during treatment, and 1 month after the end of CRT. Results: Global QOL showed a statistically significant and borderline clinically significant decrease during CRT (-9.50, P=.0024) but returned to baseline 1 month after the end of treatment (-0.33, P=.9205). Symptoms during treatment were mostly gastrointestinal (nausea/vomiting +9.94, P

UR - http://www.scopus.com/inward/record.url?scp=84871372971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871372971&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2012.09.006

DO - 10.1016/j.ijrobp.2012.09.006

M3 - Article

C2 - 23058059

AN - SCOPUS:84871372971

VL - 85

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -